Findings

What do systematic reviews say?

954 questions · 963 findings · 130 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 181 · 18.8%GRADE not reported 71 · 7.4%Very low 163 · 16.9%Low 311 · 32.3%Moderate 163 · 16.9%High 74 · 7.7%

WIBP‐CorV – Sinopharm‐Wuhan vs placebo

Confirmed SARS‐CoV‐2 infection

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25449 participants
High

WIBP‐CorV – Sinopharm‐Wuhan vs placebo

Confirmed symptomatic COVID‐19b

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25480 participants
High

WIBP‐CorV – Sinopharm‐Wuhan vs placebo

Severe or critical COVID‐19

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

WIBP‐CorV – Sinopharm‐Wuhan vs placebo

All‐cause mortalityÂ

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

WIBP‐CorV – Sinopharm‐Wuhan vs placebo

Systemic reactogenicity events

WIBP‐CorV – Sinopharm‐Wuhan showed no clear difference in systemic reactogenicity eventse compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.99 [0.95, 1.03]
2 studies · 27029 participants
High

WIBP‐CorV – Sinopharm‐Wuhan vs placebo

Any adverse eventh

WIBP‐CorV – Sinopharm‐Wuhan leads to lower any adverse eventh compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.96 [0.93, 0.98]
2 studies · 27029 participants
High

BNT162b2 – Pfizer/BioNTech + Fosun Pharma vs placebo

Serious adverse eventsi

BNT162b2 – Pfizer/BioNTech + Fosun Pharma showed no clear difference in serious adverse eventsi compared with placebo (low certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 1.3 [0.55, 3.07]
2 studies · 46107 participants
Low

WIBP‐CorV – Sinopharm‐Wuhan vs placebo

Serious adverse eventsi

WIBP‐CorV – Sinopharm‐Wuhan showed no clear difference in serious adverse eventsi compared with placebo (low certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.83 [0.6, 1.15]
2 studies · 27029 participants
Low

WIBP‐CorV – Sinopharm‐Wuhan vs placebo

Local reactogenicity events

WIBP‐CorV – Sinopharm‐Wuhan leads to lower local reactogenicity eventsk compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.88 [0.85, 0.92]
2 studies · 27029 participants
High

BBIBP‐CorV – Sinopharm‐Beijing vs placebo

Confirmed SARS‐CoV‐2 infection

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25435 participants
High

BBIBP‐CorV – Sinopharm‐Beijing vs placebo

Confirmed symptomatic COVID‐19b

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25463 participants
High

BBIBP‐CorV – Sinopharm‐Beijing vs placebo

Severe or critical COVID‐19

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

BBIBP‐CorV – Sinopharm‐Beijing vs placebo

All‐cause mortality

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

BBIBP‐CorV – Sinopharm‐Beijing vs placebo

Systemic reactogenicity events

BBIBP‐CorV – Sinopharm‐Beijing showed no clear difference in systemic reactogenicity eventse compared with placebo (moderate certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 1.05 [0.86, 1.28]
3 studies · 27540 participants
Moderate

BBIBP‐CorV – Sinopharm‐Beijing vs placebo

Any adverse eventh

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 26924 participants
Low

BBIBP‐CorV – Sinopharm‐Beijing vs placebo

Serious adverse eventsk

BBIBP‐CorV – Sinopharm‐Beijing showed no clear difference in serious adverse eventsk compared with placebo (low certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.76 [0.54, 1.06]
1 study · 26924 participants
Low

BBIBP‐CorV – Sinopharm‐Beijing vs placebo

Local reactogenicity events

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 26924 participants
Low

BNT162b2 – Pfizer/BioNTech + Fosun Pharma vs placebo

Local reactogenicity events

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

BBV152 – Bharat Biotech vs placebo

Confirmed SARS‐CoV‐2 infection

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 6289 participants
High

BBV152 – Bharat Biotech vs placebo

Confirmed symptomatic COVID‐19b

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16973 participants
High